Subramanian N, Whitmore W L, Slotkin T A
J Neurosci. 1981 Jun;1(6):674-8. doi: 10.1523/JNEUROSCI.01-06-00674.1981.
To determine whether neuronal histamine influences development of histamine H-1 receptors in the rat brain, neonates were given diphenhydramine, an H-1 antagonist, daily for the first 21 days of postnatal life. In control rats, specific H-1 binding of [3H]mepyramine in whole brain was low at birth and increased progressively toward adult levels by the end of the 3rd week. Animals treated with diphenhydramine showed marked elevations in binding as early as 4 days postnatally and the differences persisted throughout the experimental period. The increased binding in treated rats was specific to treatment with H-1 antagonists (diphenhydramine, mepyramine) as opposed to an H-2 antagonist (cimetidine); the alteration reflected enhancement of the number of binding sites without a change in Kd, a finding indicative of H-1 receptor supersensitivity. Similar results were seen in the hypothalamus, an area rich in neuronal histaminergic projections. Levels of histamine in the hypothalamus were unaffected by diphenhydramine administration until the end of the 3rd week, at which time, increases were noted. After the loading of the hypothalamus with [3H]histamine, release of label by K+ depolarization in vitro (an indirect index of release from the neuronal histamine pool) was readily obtained at all ages and was unaffected by diphenhydramine administration. Diphenhydramine did not alter histamine levels in brain regions in which most of the histamine is non-neuronal. These studies suggest that, even early in the ontogenesis of histaminergic synapses, a sufficient proportion of releasable histamine is associated with histaminergic neurons to enable trans-synaptic modulation of development of histaminergic H-1 receptors; consequently, blockade of these receptors with diphenhydramine results in supersensitivity even at the earliest stages of development.
为了确定神经元组胺是否影响大鼠脑中组胺H-1受体的发育,在新生大鼠出生后的前21天,每天给予其H-1拮抗剂苯海拉明。在对照大鼠中,出生时全脑中[3H]美吡拉敏的特异性H-1结合较低,并在第3周结束时逐渐增加至成年水平。用苯海拉明治疗的动物在出生后4天就显示出结合显著升高,并且这种差异在整个实验期间持续存在。与H-2拮抗剂(西咪替丁)相比,用H-1拮抗剂(苯海拉明、美吡拉敏)治疗的大鼠结合增加具有特异性;这种改变反映了结合位点数量的增加,而Kd没有变化,这一发现表明存在H-1受体超敏反应。在下丘脑(一个富含神经元组胺能投射的区域)也观察到了类似的结果。直到第3周结束时,苯海拉明给药才使下丘脑的组胺水平受到影响,此时观察到组胺水平有所增加。用[3H]组胺装载下丘脑后,在所有年龄段体外K+去极化引起的标记物释放(神经元组胺池释放的间接指标)都很容易获得,并且不受苯海拉明给药的影响。苯海拉明不会改变脑中大部分组胺为非神经元性的区域的组胺水平。这些研究表明,即使在组胺能突触的个体发育早期,可释放组胺的足够比例与组胺能神经元相关联,从而能够对组胺能H-1受体的发育进行跨突触调节;因此,即使在发育的最早阶段,用苯海拉明阻断这些受体也会导致超敏反应。